GPC3 and hepatocellular carcinoma: In hepatocellular carcinoma, both antibody-mediated targeting of GPC3 and chimeric antigen receptor T-cell (CAR-T) therapy directed against GPC3 have demonstrated efficacy in suppressing WNT signaling [76,80].